Medline (NASDAQ:MDLN) Insider Douglas Golwas Sells 100,000 Shares

Medline (NASDAQ:MDLN) insider Douglas Golwas sold 100,000 shares of the firm’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $36.77, for a total value of $3,677,000.00. Following the completion of the transaction, the insider owned 23,899 shares in the company, valued at approximately $878,766.23. This trade represents a 80.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Medline Trading Down 1.8%

NASDAQ MDLN traded down $0.67 on Wednesday, hitting $36.42. 10,830,182 shares of the company traded hands, compared to its average volume of 7,286,265. The firm has a market cap of $47.84 billion and a P/E ratio of 113.81. The company has a quick ratio of 2.51, a current ratio of 4.41 and a debt-to-equity ratio of 0.65. The business has a 50 day simple moving average of $40.48. Medline has a 52-week low of $32.81 and a 52-week high of $50.88.

Medline (NASDAQ:MDLN) last released its earnings results on Wednesday, May 6th. The company reported $0.33 earnings per share for the quarter, beating the consensus estimate of $0.29 by $0.04. The company had revenue of $7.35 billion for the quarter. The company’s quarterly revenue was up 10.7% compared to the same quarter last year. As a group, sell-side analysts predict that Medline will post 1.49 earnings per share for the current year.

Institutional Investors Weigh In On Medline

A number of institutional investors and hedge funds have recently bought and sold shares of MDLN. Carlyle Group Inc. bought a new stake in Medline during the fourth quarter valued at about $9,042,728,000. H&F Corporate Investors X Ltd. bought a new stake in shares of Medline in the fourth quarter worth about $4,179,591,000. Vanguard Group Inc. bought a new stake in shares of Medline in the fourth quarter worth about $793,278,000. Morgan Stanley bought a new stake in shares of Medline in the fourth quarter worth about $636,807,000. Finally, Capital Research Global Investors bought a new stake in shares of Medline in the fourth quarter worth about $620,937,000.

Wall Street Analyst Weigh In

MDLN has been the topic of several analyst reports. Wells Fargo & Company lifted their target price on Medline from $42.00 to $47.00 and gave the company an “equal weight” rating in a research report on Friday, February 27th. Deutsche Bank Aktiengesellschaft set a $42.00 target price on Medline in a research report on Thursday, May 7th. Leerink Partners set a $56.00 target price on Medline in a research report on Wednesday, February 25th. Stifel Nicolaus set a $55.00 price target on Medline in a report on Wednesday, February 25th. Finally, UBS Group raised their price target on Medline from $48.00 to $57.00 and gave the company a “buy” rating in a report on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $50.54.

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.